Liver | Jotup

EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments

Retrieved on:

fredag, maj 3, 2024

Mortality, MDAX, Nephrology, Probability, EVO, Partnership, Fibrosis, Frankfurt Stock Exchange, Science, Liver, CSO, Drug development, Drug discovery, Disease, Pharmaceutical industry

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.

Key Points:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
The strategic partnership leverages Variant Bio’s cutting-edge genomic discovery capabilities and VB-Inference platform as well as Evotec’s extensive expertise in antifibrotic drug discovery.
This strategic framework allows Variant Bio to offset the early costs of drug development in exchange for a portion of the future upside.
Dr Matthias Evers, Chief Business Officer of Evotec, said: “We are excited to enter this collaboration with Variant Bio.

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

Retrieved on:

torsdag, maj 2, 2024

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.

Key Points:

The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH.
A replay of the webinar will be accessible in the investors section of 89bio’s website following the event.
He has also served as Secretary as well as President of the American Association for the Study of Liver Diseases.
He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants.

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Retrieved on:

torsdag, april 25, 2024

Doctor of Philosophy, Infection, Safety, Pandemic, Pharmacokinetics, ESCMID, Science, Therapy, Liver, MBA, Government, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.
The presentation highlights ALG-097558 Phase 1 data showing that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.
“We are pleased to present these ALG-097558 data, which further highlight the best-in-class potential of this pan-coronavirus protease inhibitor and its substantial differentiation versus current standard of care coronavirus antiviral drugs like nirmatrelvir/ritonavir (PAXLOVIDTM),” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
“These data further demonstrate that Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

Retrieved on:

torsdag, april 25, 2024

Doctor of Philosophy, RET, MASH, News, Friends, Disease, Therapy, Liver, Patient, Principal, Plasma protein binding, MBA, SAN

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col (Ret.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col (Ret.
), FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction-associated steatohepatitis (MASH) subjects.
“On behalf of the entire Aligos team, we are deeply saddened by the news of Dr. Harrison’s passing,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
“Dr.

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

Retrieved on:

torsdag, april 25, 2024

University, Cas9, Regeneron Pharmaceuticals, Tissue, Gene editing, Nobel Prize, Mammoth, University of California, Berkeley, Research, AAV, Nobel Prize in Chemistry, Vivisection, Senior, Liver, Patient, Genome, Mammoth Biosciences, Pharmaceutical industry

TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Regeneron is developing adeno-associated viral vectors (AAVs) using antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types. Mammoth is developing novel ultracompact nucleases and associated gene editing systems, with a variety of editing functionalities at a significantly smaller size than other CRISPR-based systems, including first generation Cas9 nucleases. By leveraging Regeneron’s expertise in AAV and antibody engineering and Mammoth’s expertise in ultracompact gene editing systems, the teams will endeavor to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.

Key Points:

TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.
Mammoth is developing novel ultracompact nucleases and associated gene editing systems, with a variety of editing functionalities at a significantly smaller size than other CRISPR-based systems, including first generation Cas9 nucleases.
“We believe in the incredible power of gene editing, which we are utilizing in our diverse preclinical and clinical genetic medicines pipeline.
We look forward to working with Regeneron to enable all-in-one AAV delivery and unlock the true potential of in vivo gene editing,” said Trevor Martin, Ph.D., co-founder and Chief Executive Officer of Mammoth Biosciences.

Recovering Patient Reunites with Penn Highlands DuBois Trauma Team Who Saved His Life

Retrieved on:

onsdag, april 24, 2024

He was transported to the Level II Trauma Center at Penn Highlands DuBois where the Trauma Team saved his life.

Key Points:

He was transported to the Level II Trauma Center at Penn Highlands DuBois where the Trauma Team saved his life.
Richmond required extensive surgery,” explained Philip S. Vuocolo, MD, MHA, FACS, a board-certified acute-care and trauma surgeon at Penn Highlands General Surgery and Trauma Medical Director for Penn Highlands DuBois.
On April 23, 2024 during a meeting with the Trauma Team and emergency services personnel, they expressed gratitude to the team who saved his life.
“I am very thankful that we have such a skilled Trauma Team and Trauma Center in our region and I will never hesitate to travel from York to DuBois for my care.”
Penn Highlands DuBois is accredited as a Level II Trauma Center by the Pennsylvania Trauma Systems Foundation.

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

Retrieved on:

onsdag, april 24, 2024

Patient, Safety, Pollen, RNA, Allergen, Liver, Allergy, NASAR, Season, ANCOVA, Therapy, MITES, Pharmaceutical industry

HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). The peer-reviewed article appeared in Allergy,1 which is published by the European Academy of Allergy and Clinical Immunology and recognizes as one of the highest-ranking journals in the field of allergology. Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.

Key Points:

Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.
The primary efficacy endpoint was the reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS; ANCOVA model).
Patients and investigators rated the efficacy of treatment as significantly better with Bentrio compared to saline control (both p
From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries.

Dr. Scharles Konadu Joins TDDC in Fort Worth

Retrieved on:

onsdag, april 24, 2024

Gastroenterology, Learning, Cancer, Duke University, GI, Patient, Liver, Colonoscopy, Endoscopy, Trust, Health, Consultant, IBS, Health insurance

Fort Worth, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Texas Digestive Disease Consultants is excited to welcome Dr. Scharles Konadu, a multi-talented rising star in the gastroenterology field who practices with compassion by building relationships with her patients that is anchored on trust and mutual respect.

Key Points:

Fort Worth, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Texas Digestive Disease Consultants is excited to welcome Dr. Scharles Konadu, a multi-talented rising star in the gastroenterology field who practices with compassion by building relationships with her patients that is anchored on trust and mutual respect.
Dr. Konadu treats all GI issues, but focuses on colon cancer prevention and IBS.
Dr. Konadu is affiliated with the American Board of Internal Medicine Gastroenterology, is recognized as a Rising Star Top Doc and received her doctorate from Duke University before completing her residency and fellowship at same.
TDDC is at 900 West Magnolia in Fort Worth, TX and is open Monday through Friday, 8:30 a.m. to 4:30 p.m.

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

Retrieved on:

måndag, april 22, 2024

Hope, Hearing loss, Tissue, Regeneron Pharmaceuticals, Gene silencing, Abstract, Gene editing, Cell, Genetics, Senior, Liver, Patient, Gene, Society, Antibody, Clinical trial, Head, Pharmaceutical industry

TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024. Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression. The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.

Key Points:

Data from 10 abstracts, including six oral presentations, provide insight on Regeneron’s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression.
The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.
“Regeneron continues to advance methods to overcome these obstacles through our proprietary delivery approaches utilizing next-generation viral vectors, particularly specific retargeting antibodies and innovative payloads.
The ASGCT presentation will build on promising early results in the first patient,” said Aris Baras, M.D., Senior Vice President, Co-Head of Regeneron Genetic Medicines and Head, Regeneron Genetics Center®.

Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on:

måndag, april 22, 2024

CRISPR, Impact, Compact, Cell, CGT, PCSK9, PH1, STMN2, Liver, Gene, Society, ALS, Messenger, HAO1, NHP, Engineering, Medical device

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced four upcoming presentations at the 2024 American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11 in Baltimore, Maryland.

Key Points:

Arbor will present in vivo NHP data supporting clinical development of ABO-101, its most advanced gene editing therapeutic candidate designed to address primary hyperoxaluria type 1 (PH1) through inactivation of the HAO1 gene in the liver.
The company also will present data supporting its end-to-end nuclease development platform in a third presentation outlining the discovery and optimization of a unique, compact nuclease, termed ABR-004.
Proof-of-concept data in non-human primates show potent, therapeutically relevant silencing of PCSK9 in vivo with the novel nuclease, signaling opportunities for broader therapeutic applications.
Together, the suite of presentations will demonstrate the utility of Arbor’s proprietary discovery and development approach for enabling efficient identification and optimization of novel nucleases.